-+ 0.00%
-+ 0.00%
-+ 0.00%

Innovent Phase 3 STAR trial shows efdamrofusp alfa meets primary endpoint in nAMD with 72.8% at Q16W dosing

Reuters·03/24/2026 00:00:22

Please log in to view news